Hantz Financial Services’s Arbutus Biopharma ABUS Stock Holding History

Hantz Financial Services’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2K	Hold	521	–	–	﹤0.01%	2269
2025 Q4	$3K	Buy	521 +171	+49%	+$769	﹤0.01%	2196
2025 Q3	$2K	Hold	350	–	–	﹤0.01%	2139
2025 Q2	$1K	Hold	350	–	–	﹤0.01%	2045
2025 Q1	$1K	Hold	350	–	–	﹤0.01%	1450
2024 Q4	$1K	Hold	350	–	–	﹤0.01%	1011
2024 Q3	$1K	Hold	350	–	–	﹤0.01%	993
2024 Q2	$1K	Hold	350	–	–	﹤0.01%	981
2024 Q1	$1K	Hold	350	–	–	﹤0.01%	1094
2023 Q4	$1K	Hold	350	–	–	﹤0.01%	1055
2023 Q3	$1K	Hold	350	–	–	﹤0.01%	1049
2023 Q2	$1K	Hold	350	–	–	﹤0.01%	1014
2023 Q1	$1K	Hold	350	–	–	﹤0.01%	1031
2022 Q4	$1K	Hold	350	–	–	﹤0.01%	998
2022 Q3	$1K	Hold	350	–	–	﹤0.01%	995
2022 Q2	$1K	Hold	350	–	–	﹤0.01%	973
2022 Q1	$1K	Buy	+350	New	+$1.07K	﹤0.01%	978

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Hantz Financial Services's ABUS Position: Q1 2026 in Review

Hantz Financial Services held its Arbutus Biopharma (ABUS) position steady in Q1 2026 at 521 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #2269.

Hantz Financial Services first reported a position in ABUS in Q1 2022 and has held it in 17 quarters since. The position peaked at $3K in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

Hantz Financial Services held 521 shares of Arbutus Biopharma worth $2K as of Q1 2026.
Hantz Financial Services left its Arbutus Biopharma share count unchanged in Q1 2026.
Arbutus Biopharma made up ﹤0.01% of Hantz Financial Services's portfolio in Q1 2026, its #2269 holding.
Hantz Financial Services first reported a position in Arbutus Biopharma in Q1 2022 and has held it in 17 quarters since.
Hantz Financial Services's Arbutus Biopharma position peaked at $3K in Q4 2025.
167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Hantz Financial Services's 13F filing for Q1 2026, filed 1 May 2026.